Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

NGNE

Neurogene (NGNE)

Neurogene Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NGNE
FechaHoraFuenteTítuloSímboloCompañía
18/11/202416:25Business WireNeurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
18/11/202405:45Business WireNeurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
11/11/202415:01Business WireNeurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
04/11/202406:30Business WireNeurogene Announces Oversubscribed $200 Million Private PlacementNASDAQ:NGNENeurogene Inc
21/10/202406:30Business WireNeurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
09/08/202406:30Business WireNeurogene Reports Second Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
07/08/202406:30Business WireNeurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
02/07/202406:30Business WireNeurogene to Participate in BMO Genetic Medicines SummitNASDAQ:NGNENeurogene Inc
01/07/202406:30Business WireNeurogene Announces Addition to Russell 3000® IndexNASDAQ:NGNENeurogene Inc
18/06/202408:26Business WireNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
05/06/202406:30Business WireNeurogene to Participate in Upcoming ConferencesNASDAQ:NGNENeurogene Inc
03/06/202406:30Business WireNeurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot ProgramNASDAQ:NGNENeurogene Inc
10/05/202406:30Business WireNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
07/05/202405:19Business WireNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingNASDAQ:NGNENeurogene Inc
22/04/202415:36Business WireNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingNASDAQ:NGNENeurogene Inc
18/03/202415:14Business WireNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
04/03/202406:30Business WireNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialNASDAQ:NGNENeurogene Inc
29/02/202406:30Business WireNeurogene to Participate in Upcoming Investor ConferencesNASDAQ:NGNENeurogene Inc
16/01/202406:00Business WireNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNASDAQ:NGNENeurogene Inc
05/01/202406:00Business WireNeurogene Announces Business Update and 2024 OutlookNASDAQ:NGNENeurogene Inc
 Showing the most relevant articles for your search:NASDAQ:NGNE

Su Consulta Reciente